A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone

R. J. Hartmaier, A. S. Richter, R. M. Gillihan, J. Z. Sallit, S. E. Mcguire, J. Wang, A. V. Lee, C. K. Osborne, B. W. O'Malley, P. H. Brown, J. Xu, Todd Skaar, S. Philips, J. M. Rae, F. Azzouz, L. Li, J. Hayden, N. L. Henry, A. T. Nguyen, V. Stearns & 3 others D. F. Hayes, D. A. Flockhart, S. Oesterreich

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The coregulator steroid receptor coactivator (SRC)-1 increases transcriptional activity of the estrogen receptor (ER) in a number of tissues including bone. Mice deficient in SRC-1 are osteopenic and display skeletal resistance to estrogen treatment. SRC-1 is also known to modulate effects of selective ER modulators like tamoxifen. We hypothesized that single nucleotide polymorphisms (SNP) in SRC-1 may impact estrogen and/or tamoxifen action. Because the only nonsynonymous SNP in SRC-1 (rs1804645; P1272S) is located in an activation domain, it was examined for effects on estrogen and tamoxifen action. SRC-1 P1272S showed a decreased ability to coactivate ER compared with wild-type SRC-1 in multiple cell lines. Paradoxically, SRC-1 P1272S had an increased protein half-life. The Pro to Ser change disrupts a putative glycogen synthase 3 (GSK3) β phosphorylation site that was confirmed by in vitro kinase assays. Finally, knockdown of GSK3 β increased SRC-1 protein levels, mimicking the loss of phosphorylation at P1272S. These findings are similar to the GSK3 β -mediated phospho-ubiquitin clock previously described for the related coregulator SRC-3. To assess the potential clinical significance of this SNP, we examined whether there was an association between SRC-1 P1272S and selective ER modulators response in bone. SRC-1 P1272S was associated with a decrease in hip and lumbar bone mineral density in women receiving tamoxifen treatment, supporting our in vitro findings for decreased ER coactivation. In summary, we have identified a functional genetic variant of SRC-1 with decreased activity, resulting, at least in part, from the loss of a GSK3 β phosphorylation site, which was also associated with decreased bone mineral density in tamoxifen-treated women.

Original languageEnglish
Pages (from-to)220-227
Number of pages8
JournalMolecular Endocrinology
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Nuclear Receptor Coactivator 1
Tamoxifen
Phosphorylation
Bone and Bones
Estrogen Receptors
Single Nucleotide Polymorphism
Selective Estrogen Receptor Modulators
Estrogens
Bone Density
Nuclear Receptor Coactivator 3
Pelvic Bones
Glycogen Synthase
Ubiquitin

Keywords

  • Ligands: tamoxifen17β-Estradiol
  • Nursa molecule pages†: coregulators: src-1

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone. / Hartmaier, R. J.; Richter, A. S.; Gillihan, R. M.; Sallit, J. Z.; Mcguire, S. E.; Wang, J.; Lee, A. V.; Osborne, C. K.; O'Malley, B. W.; Brown, P. H.; Xu, J.; Skaar, Todd; Philips, S.; Rae, J. M.; Azzouz, F.; Li, L.; Hayden, J.; Henry, N. L.; Nguyen, A. T.; Stearns, V.; Hayes, D. F.; Flockhart, D. A.; Oesterreich, S.

In: Molecular Endocrinology, Vol. 26, No. 2, 01.02.2012, p. 220-227.

Research output: Contribution to journalArticle

Hartmaier, RJ, Richter, AS, Gillihan, RM, Sallit, JZ, Mcguire, SE, Wang, J, Lee, AV, Osborne, CK, O'Malley, BW, Brown, PH, Xu, J, Skaar, T, Philips, S, Rae, JM, Azzouz, F, Li, L, Hayden, J, Henry, NL, Nguyen, AT, Stearns, V, Hayes, DF, Flockhart, DA & Oesterreich, S 2012, 'A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone', Molecular Endocrinology, vol. 26, no. 2, pp. 220-227. https://doi.org/10.1210/me.2011-1032 Received April 8, 2011
Hartmaier, R. J. ; Richter, A. S. ; Gillihan, R. M. ; Sallit, J. Z. ; Mcguire, S. E. ; Wang, J. ; Lee, A. V. ; Osborne, C. K. ; O'Malley, B. W. ; Brown, P. H. ; Xu, J. ; Skaar, Todd ; Philips, S. ; Rae, J. M. ; Azzouz, F. ; Li, L. ; Hayden, J. ; Henry, N. L. ; Nguyen, A. T. ; Stearns, V. ; Hayes, D. F. ; Flockhart, D. A. ; Oesterreich, S. / A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone. In: Molecular Endocrinology. 2012 ; Vol. 26, No. 2. pp. 220-227.
@article{97e4e1d2b2fb48b8bba385a3febbea80,
title = "A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone",
abstract = "The coregulator steroid receptor coactivator (SRC)-1 increases transcriptional activity of the estrogen receptor (ER) in a number of tissues including bone. Mice deficient in SRC-1 are osteopenic and display skeletal resistance to estrogen treatment. SRC-1 is also known to modulate effects of selective ER modulators like tamoxifen. We hypothesized that single nucleotide polymorphisms (SNP) in SRC-1 may impact estrogen and/or tamoxifen action. Because the only nonsynonymous SNP in SRC-1 (rs1804645; P1272S) is located in an activation domain, it was examined for effects on estrogen and tamoxifen action. SRC-1 P1272S showed a decreased ability to coactivate ER compared with wild-type SRC-1 in multiple cell lines. Paradoxically, SRC-1 P1272S had an increased protein half-life. The Pro to Ser change disrupts a putative glycogen synthase 3 (GSK3) β phosphorylation site that was confirmed by in vitro kinase assays. Finally, knockdown of GSK3 β increased SRC-1 protein levels, mimicking the loss of phosphorylation at P1272S. These findings are similar to the GSK3 β -mediated phospho-ubiquitin clock previously described for the related coregulator SRC-3. To assess the potential clinical significance of this SNP, we examined whether there was an association between SRC-1 P1272S and selective ER modulators response in bone. SRC-1 P1272S was associated with a decrease in hip and lumbar bone mineral density in women receiving tamoxifen treatment, supporting our in vitro findings for decreased ER coactivation. In summary, we have identified a functional genetic variant of SRC-1 with decreased activity, resulting, at least in part, from the loss of a GSK3 β phosphorylation site, which was also associated with decreased bone mineral density in tamoxifen-treated women.",
keywords = "Ligands: tamoxifen17β-Estradiol, Nursa molecule pages†: coregulators: src-1",
author = "Hartmaier, {R. J.} and Richter, {A. S.} and Gillihan, {R. M.} and Sallit, {J. Z.} and Mcguire, {S. E.} and J. Wang and Lee, {A. V.} and Osborne, {C. K.} and O'Malley, {B. W.} and Brown, {P. H.} and J. Xu and Todd Skaar and S. Philips and Rae, {J. M.} and F. Azzouz and L. Li and J. Hayden and Henry, {N. L.} and Nguyen, {A. T.} and V. Stearns and Hayes, {D. F.} and Flockhart, {D. A.} and S. Oesterreich",
year = "2012",
month = "2",
day = "1",
doi = "10.1210/me.2011-1032 Received April 8, 2011",
language = "English",
volume = "26",
pages = "220--227",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone

AU - Hartmaier, R. J.

AU - Richter, A. S.

AU - Gillihan, R. M.

AU - Sallit, J. Z.

AU - Mcguire, S. E.

AU - Wang, J.

AU - Lee, A. V.

AU - Osborne, C. K.

AU - O'Malley, B. W.

AU - Brown, P. H.

AU - Xu, J.

AU - Skaar, Todd

AU - Philips, S.

AU - Rae, J. M.

AU - Azzouz, F.

AU - Li, L.

AU - Hayden, J.

AU - Henry, N. L.

AU - Nguyen, A. T.

AU - Stearns, V.

AU - Hayes, D. F.

AU - Flockhart, D. A.

AU - Oesterreich, S.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The coregulator steroid receptor coactivator (SRC)-1 increases transcriptional activity of the estrogen receptor (ER) in a number of tissues including bone. Mice deficient in SRC-1 are osteopenic and display skeletal resistance to estrogen treatment. SRC-1 is also known to modulate effects of selective ER modulators like tamoxifen. We hypothesized that single nucleotide polymorphisms (SNP) in SRC-1 may impact estrogen and/or tamoxifen action. Because the only nonsynonymous SNP in SRC-1 (rs1804645; P1272S) is located in an activation domain, it was examined for effects on estrogen and tamoxifen action. SRC-1 P1272S showed a decreased ability to coactivate ER compared with wild-type SRC-1 in multiple cell lines. Paradoxically, SRC-1 P1272S had an increased protein half-life. The Pro to Ser change disrupts a putative glycogen synthase 3 (GSK3) β phosphorylation site that was confirmed by in vitro kinase assays. Finally, knockdown of GSK3 β increased SRC-1 protein levels, mimicking the loss of phosphorylation at P1272S. These findings are similar to the GSK3 β -mediated phospho-ubiquitin clock previously described for the related coregulator SRC-3. To assess the potential clinical significance of this SNP, we examined whether there was an association between SRC-1 P1272S and selective ER modulators response in bone. SRC-1 P1272S was associated with a decrease in hip and lumbar bone mineral density in women receiving tamoxifen treatment, supporting our in vitro findings for decreased ER coactivation. In summary, we have identified a functional genetic variant of SRC-1 with decreased activity, resulting, at least in part, from the loss of a GSK3 β phosphorylation site, which was also associated with decreased bone mineral density in tamoxifen-treated women.

AB - The coregulator steroid receptor coactivator (SRC)-1 increases transcriptional activity of the estrogen receptor (ER) in a number of tissues including bone. Mice deficient in SRC-1 are osteopenic and display skeletal resistance to estrogen treatment. SRC-1 is also known to modulate effects of selective ER modulators like tamoxifen. We hypothesized that single nucleotide polymorphisms (SNP) in SRC-1 may impact estrogen and/or tamoxifen action. Because the only nonsynonymous SNP in SRC-1 (rs1804645; P1272S) is located in an activation domain, it was examined for effects on estrogen and tamoxifen action. SRC-1 P1272S showed a decreased ability to coactivate ER compared with wild-type SRC-1 in multiple cell lines. Paradoxically, SRC-1 P1272S had an increased protein half-life. The Pro to Ser change disrupts a putative glycogen synthase 3 (GSK3) β phosphorylation site that was confirmed by in vitro kinase assays. Finally, knockdown of GSK3 β increased SRC-1 protein levels, mimicking the loss of phosphorylation at P1272S. These findings are similar to the GSK3 β -mediated phospho-ubiquitin clock previously described for the related coregulator SRC-3. To assess the potential clinical significance of this SNP, we examined whether there was an association between SRC-1 P1272S and selective ER modulators response in bone. SRC-1 P1272S was associated with a decrease in hip and lumbar bone mineral density in women receiving tamoxifen treatment, supporting our in vitro findings for decreased ER coactivation. In summary, we have identified a functional genetic variant of SRC-1 with decreased activity, resulting, at least in part, from the loss of a GSK3 β phosphorylation site, which was also associated with decreased bone mineral density in tamoxifen-treated women.

KW - Ligands: tamoxifen17β-Estradiol

KW - Nursa molecule pages†: coregulators: src-1

UR - http://www.scopus.com/inward/record.url?scp=84863012220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863012220&partnerID=8YFLogxK

U2 - 10.1210/me.2011-1032 Received April 8, 2011

DO - 10.1210/me.2011-1032 Received April 8, 2011

M3 - Article

VL - 26

SP - 220

EP - 227

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 2

ER -